A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging

Claudia Kawas, S. Resnick, A. Morrison, R. Brookmeyer, M. Corrada, A. Zonderman, C. Bacal, D. Donnell Lingle, E. Metter

Research output: Contribution to journalArticle

Abstract

Previous reports have suggested that estrogen replacement therapy (ERT) in women may exert a protective effect on their risk of developing Alzheimer's disease (AD). We investigated this relationship in the Baltimore Longitudinal Study of Aging (BLSA), a prospective multidisciplinary study of normal aging conducted by the National Institute on Aging. The sample consisted of 472 post-or perimenopausal women followed for up to 16 years in the BLSA. We documented ERT prospectively at each BLSA visit, and we categorized women who had used oral or transdermal estrogens at anytime as ERT users. We used Cox proportional hazards models with time-dependent covariates to estimate the relative risk of developing AD after ERT as compared with women who had not used estrogen replacement. Approximately 45% of the women in the cohort had used ERT, and we diagnosed 34 incident cases of AD (NINCDS/ADRDA criteria) during follow-up, including nine estrogen users. After adjusting for education, the relative risk for AD in ERT users as compared with nonusers was 0.46 (95% CI, 0.209-0.997), indicating a reduced risk of AD for women who had reported the use of estrogen. Our data did not show an effect for duration of ERT usage. Our finding offers additional support for a protective influence of estrogen in AD. Randomized clinical trials are necessary to confirm this association, which could have significant public health impact.

Original languageEnglish (US)
Pages (from-to)1517-1521
Number of pages5
JournalNeurology
Volume48
Issue number6
StatePublished - Jun 1997

Fingerprint

Baltimore
Estrogen Replacement Therapy
Longitudinal Studies
Alzheimer Disease
Prospective Studies
Estrogens
National Institute on Aging (U.S.)
Proportional Hazards Models
Randomized Controlled Trials
Public Health
Education

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Kawas, C., Resnick, S., Morrison, A., Brookmeyer, R., Corrada, M., Zonderman, A., ... Metter, E. (1997). A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology, 48(6), 1517-1521.

A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease : The Baltimore Longitudinal Study of Aging. / Kawas, Claudia; Resnick, S.; Morrison, A.; Brookmeyer, R.; Corrada, M.; Zonderman, A.; Bacal, C.; Donnell Lingle, D.; Metter, E.

In: Neurology, Vol. 48, No. 6, 06.1997, p. 1517-1521.

Research output: Contribution to journalArticle

Kawas, C, Resnick, S, Morrison, A, Brookmeyer, R, Corrada, M, Zonderman, A, Bacal, C, Donnell Lingle, D & Metter, E 1997, 'A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging', Neurology, vol. 48, no. 6, pp. 1517-1521.
Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology. 1997 Jun;48(6):1517-1521.
Kawas, Claudia ; Resnick, S. ; Morrison, A. ; Brookmeyer, R. ; Corrada, M. ; Zonderman, A. ; Bacal, C. ; Donnell Lingle, D. ; Metter, E. / A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease : The Baltimore Longitudinal Study of Aging. In: Neurology. 1997 ; Vol. 48, No. 6. pp. 1517-1521.
@article{ffc5c112b07b4934912ce636a8d8b204,
title = "A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging",
abstract = "Previous reports have suggested that estrogen replacement therapy (ERT) in women may exert a protective effect on their risk of developing Alzheimer's disease (AD). We investigated this relationship in the Baltimore Longitudinal Study of Aging (BLSA), a prospective multidisciplinary study of normal aging conducted by the National Institute on Aging. The sample consisted of 472 post-or perimenopausal women followed for up to 16 years in the BLSA. We documented ERT prospectively at each BLSA visit, and we categorized women who had used oral or transdermal estrogens at anytime as ERT users. We used Cox proportional hazards models with time-dependent covariates to estimate the relative risk of developing AD after ERT as compared with women who had not used estrogen replacement. Approximately 45{\%} of the women in the cohort had used ERT, and we diagnosed 34 incident cases of AD (NINCDS/ADRDA criteria) during follow-up, including nine estrogen users. After adjusting for education, the relative risk for AD in ERT users as compared with nonusers was 0.46 (95{\%} CI, 0.209-0.997), indicating a reduced risk of AD for women who had reported the use of estrogen. Our data did not show an effect for duration of ERT usage. Our finding offers additional support for a protective influence of estrogen in AD. Randomized clinical trials are necessary to confirm this association, which could have significant public health impact.",
author = "Claudia Kawas and S. Resnick and A. Morrison and R. Brookmeyer and M. Corrada and A. Zonderman and C. Bacal and {Donnell Lingle}, D. and E. Metter",
year = "1997",
month = "6",
language = "English (US)",
volume = "48",
pages = "1517--1521",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease

T2 - The Baltimore Longitudinal Study of Aging

AU - Kawas, Claudia

AU - Resnick, S.

AU - Morrison, A.

AU - Brookmeyer, R.

AU - Corrada, M.

AU - Zonderman, A.

AU - Bacal, C.

AU - Donnell Lingle, D.

AU - Metter, E.

PY - 1997/6

Y1 - 1997/6

N2 - Previous reports have suggested that estrogen replacement therapy (ERT) in women may exert a protective effect on their risk of developing Alzheimer's disease (AD). We investigated this relationship in the Baltimore Longitudinal Study of Aging (BLSA), a prospective multidisciplinary study of normal aging conducted by the National Institute on Aging. The sample consisted of 472 post-or perimenopausal women followed for up to 16 years in the BLSA. We documented ERT prospectively at each BLSA visit, and we categorized women who had used oral or transdermal estrogens at anytime as ERT users. We used Cox proportional hazards models with time-dependent covariates to estimate the relative risk of developing AD after ERT as compared with women who had not used estrogen replacement. Approximately 45% of the women in the cohort had used ERT, and we diagnosed 34 incident cases of AD (NINCDS/ADRDA criteria) during follow-up, including nine estrogen users. After adjusting for education, the relative risk for AD in ERT users as compared with nonusers was 0.46 (95% CI, 0.209-0.997), indicating a reduced risk of AD for women who had reported the use of estrogen. Our data did not show an effect for duration of ERT usage. Our finding offers additional support for a protective influence of estrogen in AD. Randomized clinical trials are necessary to confirm this association, which could have significant public health impact.

AB - Previous reports have suggested that estrogen replacement therapy (ERT) in women may exert a protective effect on their risk of developing Alzheimer's disease (AD). We investigated this relationship in the Baltimore Longitudinal Study of Aging (BLSA), a prospective multidisciplinary study of normal aging conducted by the National Institute on Aging. The sample consisted of 472 post-or perimenopausal women followed for up to 16 years in the BLSA. We documented ERT prospectively at each BLSA visit, and we categorized women who had used oral or transdermal estrogens at anytime as ERT users. We used Cox proportional hazards models with time-dependent covariates to estimate the relative risk of developing AD after ERT as compared with women who had not used estrogen replacement. Approximately 45% of the women in the cohort had used ERT, and we diagnosed 34 incident cases of AD (NINCDS/ADRDA criteria) during follow-up, including nine estrogen users. After adjusting for education, the relative risk for AD in ERT users as compared with nonusers was 0.46 (95% CI, 0.209-0.997), indicating a reduced risk of AD for women who had reported the use of estrogen. Our data did not show an effect for duration of ERT usage. Our finding offers additional support for a protective influence of estrogen in AD. Randomized clinical trials are necessary to confirm this association, which could have significant public health impact.

UR - http://www.scopus.com/inward/record.url?scp=0030748719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030748719&partnerID=8YFLogxK

M3 - Article

C2 - 9191758

AN - SCOPUS:0030748719

VL - 48

SP - 1517

EP - 1521

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -